𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cellular immune responses in hepatitis B virus e antigen negative chronic hepatitis B

✍ Scribed by D. Vassilopoulos; I. Rapti; M. Nikolaou; E. Hadziyannis; S. J. Hadziyannis

Book ID
108886151
Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
260 KB
Volume
0
Category
Article
ISSN
1352-0504

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hepatitis B virus DNA prediction rules f
Hepatitis B virus DNA prediction rules for hepatitis B e antigen–negative chronic hepatitis B
✍ Jordan J. Feld; Melissa Ayers; Dahlia El-Ashry; Tony Mazzulli; Raymond Tellier; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 672 KB

After hepatitis B e antigen (HBeAg) seroconversion, hepatitis B may become inactive or progress to HBeAg-negative hepatitis with persistent or intermittent alanine aminotransferase (ALT) elevation. The aim of this study was to prospectively identify factors predictive of the clinical course in HBeAg

Serum hepatitis B virus-DNA cutoff level
Serum hepatitis B virus-DNA cutoff levels in hepatitis B e antigen–negative chronic hepatitis B virus infection
✍ George V. Papatheodoridis; Emanuel K. Manesis; Spilios Manolakopoulos; Athanasio 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB 👁 2 views

Commitment of bone marrow cells to hepatic stellate cells in mouse. J Hepatol 2004;40:255-260. 6. Kisseleva T, Uchinami H, Feirt N, Quintana-Bustamante O, Segovia JC, Schwabe RF, et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 2006;45:429-438. 7. Magnes

Hepatitis B e antigen–negative chronic h
Hepatitis B e antigen–negative chronic hepatitis b in Hong Kong
✍ Henry L. Y. Chan; Nancy W. Y. Leung; Munira Hussain; May L. Wong; Anna S. F. Lok 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

Hepatitis B e antigen-negative chronic hepatitis B (eϪCHB) has been reported in Asia but its prevalence and clinical significance have not been determined. The aims of this study were to determine the prevalence of eϪCHB in Hong Kong and the frequency of precore and core promoter mutations in these

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60

Humoral and cellular immune responses to
Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen-carrier children who cleared serum- hepatitis B surface antigen
✍ H Hsu; M Chang; R Hsieh; Y Ni; W Chi 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB 👁 2 views

Abbreviations: HBsAg, hepatitis B surface antigen; anti-HBs, hepatitis B surface antimonths. 2 From the 415 children, we recruited 16 chronically infected gen antibody; HBV, hepatitis B virus; PCR, polymerase chain reaction; PBMC, peripheral children who had cleared serum HBsAg for more than 2 years